Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
Jadwiga A Wedzicha,1 Nanshan Zhong,2 Masakazu Ichinose,3 Michael Humphries,4 Robert Fogel,5 Chau Thach,5 Francesco Patalano,6 Donald Banerji5 1National Heart and Lung Institute, Imperial College London, London, UK; 2State Key Laboratory of Respiratory Disease, National Clinical Research Center of Re...
Main Authors: | Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-01-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/indacaterolglycopyrronium-versus-salmeterolfluticasone-in-asian-patien-peer-reviewed-article-COPD |
Similar Items
-
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
by: Jadwiga A. Wedzicha, et al.
Published: (2019-01-01) -
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
by: Leif Bjermer, et al.
Published: (2017-12-01) -
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
by: Antonio R. Anzueto, et al.
Published: (2018-06-01) -
Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach
by: Lakhotia B, et al.
Published: (2020-04-01) -
Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01)